ClinicalTrials.gg
RecruitingNCT05491200Updated Jul 2, 2026

Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

A Phase 4 interventional study of Prasugrel based short DAPT and Prasugrel based standard DAPT in ST Elevated Myocardial Infarction and Dual Antiplatelet Therapy, sponsored by Research Maatschap Cardiologen Rotterdam Zuid. Recruiting at 27 sites in 6 countries. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Research Maatschap Cardiologen Rotterdam Zuid · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,656
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in ST Elevation Myocardial Infarction with a site in Netherlands — 4 open to participants now, 8 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Netherlands.

Planned enrollment
12th of 34
1,656 · median 457
Started
2022
with 2 others
Phase 4
9 of 43
3 open now
Registered
37th of 43
by date

Among the 43 studies in ST Elevation Myocardial Infarction with a site in Netherlands, this one is the 12th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2022, is one of 9 in phase 4, and was the 37th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

4 of the 43 studies in ST Elevation Myocardial Infarction with a site in Netherlands are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in ST Elevation Myocardial Infarction with a site in Netherlands, or all of them as a file.
02

Study summary

The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard DAPT regimen in STEMI patients in terms of safety and efficacy endpoints.

In the subgroup of STEMI patients with MVD, a sub-randomization will allow a comparison between a complete revascularization OCT-guided versus complete revascularization angiography-guided stent in terms of efficacy and safety endpoints.

Read the detailed description

Consecutive patients with STEMI planned for pPCI will be screened for eligibility criteria and treated as per standard of care with ASA and Prasugrel 60 mg loading dose. The culprit lesion will be treated during the index procedure. Non culprit lesions in patients with MVD will be treated during staged procedure(s), in any case last instalment of staged procedure(s) should be scheduled within 15 days after index procedure. Complete revascularization of non culprit lesions will be allocated to either OCT- or angio-guided strategy (OCT randomization). At 30-45 days follow-up after index procedure, if inclusion criteria are met, patients will be randomized to prasugrel monotherapy or standard DAPT regimen (DAPT randomization).

The follow-up duration is 35 months after DAPT randomization, i.e. clinical outcomes will be analysed at 11 and 35 months after DAPT randomization.

03

Conditions studied

  • ST Elevated Myocardial Infarction
  • Dual Antiplatelet Therapy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligibility at index procedure

All STEMI patients who are planned to be treated with PCI:

ST segment elevation myocardial infarction

Chest discomfort suggestive of cardiac ischemia ≥20 min at rest with 1 of the following features:

  • ST segment elevation ≥2 contiguous ECG leads
  • new or presumably new left bundle branch block

In patients with multivessel disease, treatment only of the culprit lesion / target vessel during primary PCI is recommended.

Eligibility at 30-45 days

  • All patients who have provided
  • Compliance to DAPT with no regimen modifications (Non-adherence Academic Research Consortium 0)
  • No occurrence of significant event (such as MI, unplanned revascularisation, stent thrombosis, stroke, major vascular complication/bleeding BARC Types 3 or greater).
  • Successful revascularization: - Successful delivery and deployment of the Study device(s), with final residual stenosis of \<30% (visually) for all target lesions.
  • Complete revascularization performed when more than 1 significant lesion, during the index procedure or in staged procedure(s) occurring within 15 days from the index procedure. Physiologic assessment highly recommended for lesions with stenosis between 50% and 90%.

Exclusion criteria

Exclusion criteria

  • Patients on oral anticoagulation
  • to P2Y12 inhibitors and/or to Cardioaspirin or to any of the (, history of any stroke or within the last 12 months, active bleeding or haemorrhagic diathesis, fibrin-specific fibrinolytic therapy less than 24 h before randomization, severe hepatic dysfunction ( C), history of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines, history of gastrointestinal perforation or acute gastrointestinal ulcers, severe cardiac failure ( grade III or IV), combination with methotrexate at doses of 15 mg/week or more).
  • Patients who have received P2Y12 inhibitors other than Prasugrel in the ambulance (Ticagrelor or Clopidogrel loading dose) or are already on P2Y12 inhibitors, may be enrolled in the protocol, provided that the Prasugrel loading dose is administered at admission, according to current guidelines recommendations (see section 5.2.2).
  • Concomitant oral or i.v. therapy with strong inhibitors (e.g., ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice >1L/day), CYP3A substrates with narrow therapeutic indices (e.g., cyclosporine, quinidine), or strong CYP3A inducers (e.g., rifampin), - rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital
  • count \<100.000/μL at the time of screening
  • Anemia ( \<10 g/dL) at the time of screening
  • Comorbidities associated with \<1 year
  • Pregnancy, giving birth within the last 90 days, or lactation (see appendix III for women of )
  • PCI indication for stent thrombosis or previous history of definite stent thrombosis
  • Non-deferrable major surgery on DAPT after PCI
  • Cardiogenic shock
  • Out of hospital cardiac arrest (OHCA) unless survivors of ventricular arrythmia with prompt return of spontaneous circulation (ROSC)
  • Patients with severe renal impairment: ≤30 ml/min/1.73 m2 (as calculated by formula for estimated GFR).
  • Patients participating in another interventional (device of drug trial) within the previous 12 months or patients to whom an drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer.
  • No
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,656 participants (estimated)

Study arms

  • Experimental
    Prasugrel-based short DAPT

    Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy for 11 months.

    Drug: Prasugrel based short DAPT

  • Active comparator
    Prasugrel based standard DAPT

    Prasugrel-based DAPT for 1 year

    Drug: Prasugrel based standard DAPT

  • Experimental
    OCT guided non-culprit lesion

    Complete revascularization of non culprit lesions guided by OCT

    Device: OCT guided revascularization

  • Active comparator
    Angio guided non-culprit lesion

    Complete revascularization of non culprit lesions guided by Angio

    Device: Angio guided revascularization

Interventions

  • DrugPrasugrel based short DAPT

    Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus

  • DrugPrasugrel based standard DAPT

    Prasugrel based DAPT for 1 year

  • DeviceOCT guided revascularization

    OCT guided revascularization of the non-culprit lesions

  • DeviceAngio guided revascularization

    Angio guided revascularization of the non-culprit lesions

06

What researchers measure

Primary outcomes

  1. non inferiority of a Prasugrel-based short DAPT (30-45 days) followed by Prasugrel 11 month monotherapy versus standard 12 month DAPT regimen

    Incidence of Net Adverse Clinical Events (NACE) at 11 months post DAPT randomization as composite of all cause death, MI, stroke or BARC bleeding 3 or 5

    Time frame: 11 months

  2. superiority of an Optical Coherence Tomography (OCT)-guided revascularization completion as compared to a standard angiography-guided revascularization completion.

    Post-procedural Minimal Stent Area (MSA)

    Time frame: immediately after the procedure

Secondary outcomes

  1. Composite of MACCE

    Composite of the number of major adverse cardiac and cerebrovascular events (MACCE) defined as cardiovascular death, myocardial infarction, or ischaemic stroke

    Time frame: 3 year

  2. BARC type 3 or 5 events

    Number of BARC type 3 or 5 events occuring

    Time frame: 1 and 3 years

07

Study locations

26 of 27 sites recruiting
  • Imelda Bonheiden
    Bonheiden, Belgium
    Recruiting
    • Willem de Wilde, PhD · Contact
    • Willem de Wilde, PhD · Principal investigator
  • AZ St.Jan
    Bruges, Belgium
    Recruiting
    • Patrick Coussement, PhD · Contact
    • Patrick Coussement, PhD · Principal investigator
  • ZOL Genk
    Genk, Belgium
    Recruiting
    • Koen Amelot, PhD · Contact
    • Koen Amelot, PhD · Principal investigator
  • UZ Leuven
    Leuven, Belgium
    Recruiting
    • Tom Adreiaansen, PhD · Contact
    • Tom Adreiaansen, PhD · Principal investigator
  • AZ Delta
    Roeselare, Belgium
    Recruiting
    • Maarten v Haverbeke · Contact
    • Maarten v Haverbeke, PhD · Principal investigator
  • FN BRNO
    Brno, Czechia
    Recruiting
    • Petr Kala, PhD · Contact
    • Petr Kala, PhD · Principal investigator
  • Masaryk Hospital Usti nad Labem -
    Hradec Králové, Czechia
    Recruiting
    • Pavel Cervinka, PhD · Contact
    • Pavel Cervinka, PhD · Principal investigator
  • Charles University Hospital
    Prague, Czechia
    Not yet recruiting
    • Tomas Kovarnik, PhD · Contact
    • Tomas Kovarnik, PhD · Principal investigator
  • Asklepios Klinik Bad Oldesloe
    Bad Oldesloe, Germany
    Recruiting
    • Ralph Tölg, PhD · Contact
    • Ralph Tölg, PhD · Principal investigator
  • Segeberger Kliniken
    Bad Segeberg, Germany
    Recruiting
    • Arief Kurniadi, PhD · Contact
    • Arief Kurniadi, PhD · Principal investigator
  • University hospital Dresden
    Dresden, Germany
    Recruiting
    • Axel Linke, PhD · Contact
    • Axel Linke · Principal investigator
  • Ospedale Papa Giovanni XXIII
    Bergamo, Italy
    Recruiting
    • Paolo Angelo Canova, MD, PhD · Contactpacanova@asst-pg23.it
    • Paolo Angelo Canova, MD, PhD · Principal investigator
  • University of Ferrara
    Ferrara, Italy
    Recruiting
    • Gianluca Campo, PhD · Contact
    • Gianluca Campo, PhD · Principal investigator
  • University San Martino
    Genova, Italy
    Recruiting
    • I. Porto, PhD · Contact
    • I. Porto, PhD · Principal investigator
  • Centro Cardiologico Monzino IRCCS
    Milan, Italy
    Recruiting
  • University Federico II
    Naples, Italy
    Recruiting
    • G. Esposito, PhD · Contact
    • G. Esposito, PhD · Principal investigator
  • University Gemelli
    Roma, Italy
    Recruiting
    • F. Burzotta, PhD · Contact
    • F. Burzotta, PhD · Principal investigator
  • Amphia Ziekenhuis
    Breda, 4818 CK, Netherlands
    Recruiting
    • Rohit Oemrawsingh, PhD · ContactOemrawsingh@amphia.nl · +31765954092
    • Rohit Oemrawsingh, PhD · Principal investigator
  • Albert Schweitzer ziekenhuis
    Dordrecht, Netherlands
    Recruiting
    • J.M. Cheng, PhD · Contact
    • J.M. Cheng · Principal investigator
  • Catherina ziekenhuis
    Eindhoven, Netherlands
    Recruiting
  • RadboudUMC
    Nijmegen, Netherlands
    Recruiting
    • Niels v Royen · Contact
    • Niels v Royen, PhD · Principal investigator
  • Erasmus Medical Center
    Rotterdam, Netherlands
    Recruiting
    • Nicolas van Mieghem, PHD · Contact
    • Nicolas v Mieghem · Principal investigator
  • Maasstadziekenhuis
    Rotterdam, Netherlands
    Recruiting
  • Haga hospital
    The Hague, Netherlands
    Recruiting
    • Samer Somi, PhD · Contact
    • Samer Somi, PhD · Principal investigator
  • Institute for CVD Dedinje
    Belgrade, Serbia
    Recruiting
    • Mihajlo Farkić, PhD · Contact
    • Mihajlo Farkić, PhD · Principal investigator
  • University clinical center of Serbia
    Belgrade, Serbia
    Recruiting
    • Dejan Milasinovic, PhD · Contact
    • Dejan Milasinovic, PhD · Principal investigator
  • Institute for CVD Vojvodine
    Kamenitz, Serbia
    Recruiting
    • Milovan Petrovic, PhD · Contact
    • Milovan Petrovic, PhD · Principal investigator
08

References and documents

Publications

  • Paradies V, Van Mieghem NM, Oemrawsingh RM, Richardt G, Esposito G, Campo G, Burzotta F, Canova P, Linke A, Porto I, Trabattoni D, Teeuwen K, Adriaenssens T, Kala P, Stankovic G, Vliet RV, Giacoppo D, Daemen J, Smits PC. Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial. EuroIntervention. 2025 May 16;21(10):571-580. doi: 10.4244/EIJ-D-24-00829. PubMed 40375771 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Aug 2027, 60 months after the start.

Of 44 non-industry phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 74. This study's planned 60 months is above that.

Counting every sponsor, half of 49 studies reached it within 34 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2022
First posted
Aug 8, 2022
StartActual
Jul 22, 2022
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2029
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05491200
Lead sponsor
Research Maatschap Cardiologen Rotterdam Zuid
Responsible party
Sponsor
First posted
Aug 8, 2022
Start date
Jul 22, 2022
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Jul 2, 2026

Study contacts

Valeria Paradies, MD
Contact
paradiesV2@maasstadziekenhuis.nl
+31621620153
Ria van Vliet
Contact
vlietM@maasstadziekenhuis.nl
+31644162844
Valeria Paradies, MD, PhD
principal investigator · Research Maatschap Cardiologen Rotterdam Zuid

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion